4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop [Seeking Alpha]
4D Molecular Therapeutics (NASDAQ:FDMT) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $26.00 price target on the stock.
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease [Yahoo! Finance]
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
4DMT Announces New Employment Inducement Grants